State of Alaska Department of Revenue Has $5.55 Million Stock Position in Becton, Dickinson and Company $BDX

Key Points

• The State of Alaska Department of Revenue has decreased its stake in Becton, Dickinson and Company by 4.2% in Q2, now owning 32,248 shares valued at approximately $5.55 million.
• Becton, Dickinson and Company announced a quarterly dividend of $1.04 per share, with a payout ratio of 74.82% and an annualized dividend yield of 2.3%.
• Wall Street analysts have varied price targets on Becton, Dickinson’s stock, with a consensus target price of $213.09 and a consensus rating of "Hold".

State of Alaska Department of Revenue decreased its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 4.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,248 shares of the medical instruments supplier's stock after selling 1,400 shares during the quarter. State of Alaska Department of Revenue's holdings in Becton, Dickinson and Company were worth $5,554,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Northcape Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after purchasing an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after purchasing an additional 53 shares in the last quarter. Brady Family Wealth LLC lifted its holdings in shares of Becton, Dickinson and Company by 1.2% in the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock valued at $989,000 after purchasing an additional 53 shares in the last quarter. Diversified Trust Co lifted its holdings in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock valued at $272,000 after purchasing an additional 53 shares in the last quarter. Finally, Horizon Bancorp Inc. IN lifted its holdings in shares of Becton, Dickinson and Company by 10.9% in the first quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier's stock valued at $130,000 after purchasing an additional 56 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BDX. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Barclays dropped their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Finally, Royal Bank Of Canada began coverage on Becton, Dickinson and Company in a research note on Thursday. They issued a "sector perform" rating and a $211.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and a consensus target price of $213.09.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock worth $551,536 in the last quarter. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $184.59 on Monday. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The business has a 50-day moving average of $188.27 and a two-hundred day moving average of $188.49. The stock has a market capitalization of $52.91 billion, a P/E ratio of 33.20, a P/E/G ratio of 1.49 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. During the same quarter in the previous year, the firm earned $3.50 earnings per share. The business's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.